癌症免疫疗法
细胞因子诱导的杀伤细胞
肿瘤微环境
免疫疗法
细胞疗法
过继性细胞移植
医学
化疗
树突状细胞
免疫学
免疫系统
癌症
T细胞
临床试验
癌症研究
内科学
细胞
生物
CD8型
CD3型
遗传学
作者
Shuo Wang,Xiaoli Wang,Xinna Zhou,H. Kim Lyerly,Michael A. Morse,Jun Ren
标识
DOI:10.1080/14712598.2020.1728250
摘要
Introduction: Immunotherapy is now a standard treatment for many malignancies. Although immune checkpoint inhibition has demonstrated substantial efficacy by enhancing T cell activation and function in the tumor microenvironment, adoptive transfer of T and NK cell products promises to provide activated cells capable of immediate and direct tumor destruction. A widely applicable, non-MHC dependent, cellular therapy, consisting of in vitro generated dendritic cells (DC) combined with cytokine-induced killer cells (CIK), is highly efficient to produce from individual patients and has demonstrated safety and efficacy alone or with chemotherapy.Areas covered: We summarize the clinical data from studies of DC-CIK and discuss future research directions.Expert opinion: Patients with a wide variety of tumor types who have received DC-CIK therapy may experience clinical responses. This versatile therapy synergizes with other anti-cancer therapies including chemotherapy and immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI